This study is assessing the investigational use of a “canakinumab” and its ability to reduce risk of future heart attacks and other cardiovascular events such as a stroke. Patients will be randomized to determine if it is safe and tolerable and can help their heart disease or keep them from developing Type 2 diabetes. It is planned that about 17,200 people who have had a heart attack and who are at least 18 years old will participate in this study. Canakinumab is a drug that has the same form of antibodies, part of the immune system in all humans. Two common diseases involving inflammation are cardiovascular disease, which may exist in many forms including heart attack, stroke and even cardiovascular death, and Type 2 diabetes.
Cardiology and Diabetes
Cardiology and Diabetes
Dapagliflozin is an investigational drug that is part of a new class of drugs for diabetes. Dapagliflozin works by causing the kidneys to remove excess sugar (glucose) in the urine, which in turn helps lower the amount of sugar (glucose) in the blood. Dapagliflozin does this without the involvement of insulin. Studies have shown dapagliflozin to be effective in lowering glucose levels in the blood and in addition, in lowering body weight and blood pressure. It is thought that by better controlling the levels of glucose in the blood and by lowering body weight and blood pressure, dapagliflozin may reduce the risk of cardiovascular events, including heart attacks.
Cardiology and Diabetes
This study will compare the impact of including exenatide once weekly as part of usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary cardiovascular combined endpoint of cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke.
Cardiology and Diabetes
A multicenter, Phase III study to evaluate cardiovascular outcomes of tal-875, 50 mg in addition to standard of care in subjects with type 2 diabetes and with cardiovascular disease or multiple risk factors for cardiovascular disease.
AngelMed system for early recognition and treatment of STEMI. This Phase III study uses an implantable heart monitoring device that detects and alerts subjects to rapidly progressive ST shifts that might be indicative of thrombotic coronary occlusions. Components include programmable monitoring device (IMD), right ventricle lead, lead adapter, external alarm device (EXD) and a programmer.
ORBIT - AF
The purpose of this registry is to better understand how patients diagnosed with A-Fib are cared for by their health-care provider and what happens to them as a result of the care they receive, and in particular, the drug therapy they receive and their associated outcomes. Being enrolled in this observational registry means that you will be cared for just as you would be if you were not enrolled, however, information will be gathered from you and your health-care provider (your registry doctor).
ST monitoring to detect ACS events in ICD patients study.
A Phase III study for bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery.
Prospective Multicenter Imaging Study for Evaluation of Chest Pain. The objective is to determine whether an initial non-invasive anatomic imaging strategy with coronary CT angiography (CTA) will improve clinical outcomes in subjects with symptoms concering for coronary artery disease relative to an initial functional testing strategy (standard care).
Absorb™ is an investigational bioabsorbable vascular scaffold manufactured by Abbott. Absorb™ is referred to as a scaffold to indicate that it is a temporary structure. Abbott's Absorb™ BVS is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures. ABSORB III™ is the first U.S. clinical trial to evaluate the potential benefits and safety of Absorb™ in comparison to a medicated metallic cardiac stent, also called a drug eluting stent, in patients with coronary artery disease (CAD).
The main purpose of this study is to test whether a drug called rivaroxaban, given alone or together with aspirin, is more effective than aspirin alone in preventing heart attacks and strokes in people with hardening of the arteries (“atherosclerosis”) involving the arteries of the heart muscle, legs, or brain. Both aspirin and rivaroxaban can cause bleeding from the lining of the stomach and small intestine. A second purpose of this study is to test whether a drug called pantoprazole (also referred to as a proton pump inhibitor or “PPI”) will prevent bleeding from the stomach and intestine when taken with rivaroxaban and aspirin. The U.S. Food and Drug Administration (FDA) has approved pantoprazole for use to treat bleeding from the lining of the stomach and small intestine. This study will test an investigational use of pantoprazole. An “investigational use” is a use that is being tested and is not approved by the FDA.
The purpose of this research study is to follow patients with a known diagnosis of coronary artery disease and have been referred for an exercise or drug stress test SPECT MPI (Single Photon-Emission Computed Tomography Myocardial Perfusion Imaging) procedure. If referred for drug stress testing, there is a reasonable potential that the patient will attempt exercise stress on a treadmill. SPECT (a type of imaging used for this study), also called cardiac rest – stress tests, are used to view blood flow in the heart to scan for damaged heart tissue and poor blood flow to the heart. The SPECT machine is a large circular device containing a camera that detects the radioactive tracer your body absorbs. During the scan, the patient will lie on a table while the SPECT machine rotates around the patient. The SPECT machine takes pictures of internal organs and other structures. The pictures are sent to a computer that uses the information to create 3-D images of your heart.
The primary objective of this study is to compare the effect of SAR236553 with placebo on the occurrence of cardiovascular events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) in patients who have experienced an acute coronary syndrome (ACS) event 4 to 16 weeks prior to randomization and are treated with intensive statin therapy (defined as atorvastatin 40 or 80 mg, or rosuvastatin 20 or 40 mg) or at maximally tolerated dose of these given statins, or other non statin LMT(s).
Pegasus TIMI 54
A Phase III, randomized, double-blind, placebo controlled, parallel group, multinational trial, to assess the prevention of thrombotic events with Ticagrelor compared to placebo on a background of acetyl salicylic acid therapy in patients with history of myocardial infarction.
Study of management strategies including pantoprazole 40 mg q.a.m. and taking Pradaxa® with food on gastrointestinal symptoms in patients newly on treatment with Pradaxa® 150 mg b.i.d. or 75 mg b.i.d. for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).